The LR-MDS failure reduces tebapivat's total addressable opportunity but does not affect the sickle cell disease catalyst due H2 2026. Monitor for any further pipeline prioritization updates and the upcoming Phase 2 sickle cell data, which is now the sole near-term catalyst for tebapivat.
Price Chart
Executive Summary
Agios Pharmaceuticals announced it will not advance tebapivat, its next-generation oral PK activator, in lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b trial failed to meet the predefined threshold for clinical benefit. The decision removes a pipeline opportunity but the company continues to evaluate tebapivat in sickle cell disease with topline data expected in H2 2026.
Key Facts
- Phase 2b trial of tebapivat in LR-MDS did not meet predefined threshold for further development
- Tebapivat showed biological activity but insufficient clinical benefit in 65-patient study
- No new safety signals were identified; drug was well tolerated
- Agios continues Phase 2 trial of tebapivat in sickle cell disease with topline data expected H2 2026
- LR-MDS program discontinuation removes a potential pipeline catalyst
Financial Impact
Pipeline setback with no disclosed financial impact; R&D costs for LR-MDS program are sunk. Sickle cell disease program remains the key value driver.
Risk Factors
- Sickle cell disease Phase 2 trial may also fail to meet endpoints
- Competing therapies for sickle cell disease may limit tebapivat's commercial potential
- Pipeline concentration risk increases with LR-MDS program discontinued
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303496 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 144 | $37.19 | awaiting T+60 | — | $36.83 (−0.97%) |
Aug 6, 2026 11w ago | Institutional Cluster | $31.95 | awaiting T+60 | — | $36.83 (+15.27%) |
Jul 30, 2026 12w ago | 8-K | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $36.83 (+12.46%) |
Jul 30, 2026 12w ago | Press Release | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $36.83 (+12.46%) |
Jul 7, 2026 15w ago | Press Release | $44.01 $33.25 | ▼ −24.45% | ▼ −26.44% | $36.83 (−16.31%) |
Jun 29, 2026 17w ago | Press Release | $38.04 $34.97 | ▼ −8.07% | ▼ −12.46% | $36.83 (−3.18%) |
Jun 18, 2026 18w ago | 8-K | $35.10 $32.81 | ▼ −6.52% | ▼ −8.27% | $36.83 (+4.93%) |
Jun 13, 2026 19w ago | Press Release | $31.82 $34.63 | ▲ +8.83% | ▲ +7.83% | $36.83 (+15.74%) |
Jun 1, 2026 21w ago | Press Release | $28.00 $33.90 | ▲ +21.07% | ▲ +19.84% | $36.83 (+31.54%) |
May 29, 2026 21w ago | Press Release | $29.40 $32.64 | ▼ −11.02% | ▼ −9.84% | $36.83 (−25.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers